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METHODS:
 
 Data on mucositis and clinical parameters
of hospitalization, IV antibiotic use, fever, analgesic use,
and parenteral nutrition were collected as part of a multi-
center clinical trial conducted in Europe (n  234). Pa-
tients were quantified as having mucositis if ulcerative
lesions were present after receiving BEAM (BCNU, Eto-
poside, Ara-C, Melphalan) HDC. Days of usage for clini-
cal parameters were quantified as resource consumption
and compared in patients with and without mucositis.
RESULTS: Mucositis showed an association with resource
consumption. Days of analgesia had the highest correla-
tion followed by antibiotic use, fever, hospitalization, and
parenteral nutrition (r  0.4128*, 0.3003*, 0.2634*,
0.2558*, 0.0973, respectively, *p  .0001). Patients with
mucositis had two additional days of hospitalization and
three additional days of IV antibiotics. Mean  s.e. for re-
source consumption is listed for patients (with mucositis,
without mucositis, p-value), as follows: days of hospital-
ization (26.8  0.4, 24.4  0.5, p  .001); days of IV an-
tibiotics (12.6  0.7, 9.5  0.7, p  .002); days of anal-
gesic use (9.2  0.7, 4.3  0.5, p  .001); days of
parenteral nutrition (1.8  0.3, 1.6  0.2, p  .668);
days of fever (2.9  0.3, 2.0  0.3, p  .035).
CONCLUSIONS: Patients with mucositis had signifi-
cantly higher resource consumption. Mucositis impacts
on length of hospitalization, days of fever, IV antibiotic,
and analgesic use.
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OBJECTIVES:
 
 The majority of patients with non-small
cell lung cancer (NSCLC) present with advanced disease,
for which pharmacological therapy is the primary treat-
ment option. Economic models are useful tools to help
decision-makers determine the cost and health impact of
existing and new therapies in their practice settings.
METHODS: A decision-analytic model was developed to
represent the progression of advanced (stage IIIB/IV)
NSCLC from diagnosis and first-line therapy to subse-
quent lines of therapy, best supportive care and death.
The model is a semi-Markov process with three-week cy-
cles and a two-year time horizon. By selecting different
sets of model parameters, it may be used to estimate cost-
of-illness (by pooling cost and health outcomes across a
range of therapies), cost-effectiveness (comparison be-
tween new or existing therapeutic options) and impact on
health-care budgets. Data sources include published clini-
cal trials, treatment patterns based on published studies,
and a panel of US clinicians and US unit costs. In this
case, the NSCLC model was used to examine the costs
and outcomes of a distribution of mono and combination
agents most commonly administered as first and second-
line therapy in the US.
RESULTS: Over one and two years respectively the aver-
age cost of therapy was $42,319 and $48,151 per pa-
tient, with an estimated survival of 40.2% and 7.4%.
The estimated cost for a health-care purchaser with a
prevalence of 100 patients with advanced NSCLC was
$4.90 million per year. If all patients used carboplatin
and paclitaxel as first-line therapy, this increased to
$5.14 million. If a new therapy increased the median time
to progression for patients on first-line therapy by two
months, the cost increased to $5.0 million per year.
CONCLUSION: This model provides a flexible analyti-
cal platform for a range of economic evaluations of alter-
native therapeutic strategies in advanced NSCLC. This is
valuable for strategic planning in Phase II/III drug devel-
opment.
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ESTIMATING THE IMPACT OF 
ANTICOAGULATION QUALITY
ON EVENT RATES
Matchar DB, Samsa GP
Duke University, Durham, NC, USA
OBJECTIVES: Warfarin anticoagulation has been shown
to effectively decrease the rate of thromboembolism (TE),
with an associated increased rate of bleeding. Maximiz-
ing the benefit and minimizing the risk depends on main-
taining patients in a narrow therapeutic range for pro-
thrombin time (measured as INR). An increased percentage
of time spent in target range (TTR) is predictive of better
clinical outcomes. However, strategies to increase TTR can
be costly. To allow local clinical policy makers to deter-
mine whether these strategies can be justified, we developed
a general approach to estimating bleeding and TE rates as-
sociated with a given population distribution of INR.
METHODS: We used data from a large cohort (Cannegi-
eter, 1995) to derive a logistic equation for baseline abso-
lute risk of bleeding as a function of INR. Based on a sep-
arate large cohort of patients (Fihn, 1993) with various
times since initiation of therapy, we derived a risk ratio
that modifies the above baseline relationship that ac-
counts for time since initiation of therapy. A similar strat-
egy was used to estimate TE, using INR and indication
(mechanical valve versus atrial fibrillation) as predictors.
RESULTS: The model for bleeding was: logit(p)  8.84 
0.83 INR  0.64 EARLY, where EARLY  1 if the pa-
tient is in the first 3 months of anticoagulation, and 0
otherwise. The final model for TE was: logit(p)  0.73
1.17 INR  0.64(AF), where AF  1 if the indication is
atrial fibrillation and 0 if the indication is mechanical
heart valve. The integral of these logistic equations,
weighted by a given population distribution of INR, pro-
vides population estimates of annual bleed and TE rates.
